Nasdaq

EDWARDS PASCAL PRECISION TRANSCATHETER MITRAL AND TRICUSPID VALVE REPAIR SYSTEM RECEIVES CE MARK

IRVINE, Calif., Aug. 17, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), today announced the company's PASCAL Precision transcatheter valve repair system received CE Mark for the ...
EurekAlert!

Novel TEER repair device meets primary endpoint in treating degenerative mitral regurgitation in patients not eligible for surgery

BOSTON – September 17, 2022 – Results of the first randomized controlled trial to directly compare two contemporary transcatheter edge-to-edge repair (TEER) devices for degenerative mitral ...
Nasdaq

EDWARDS PASCAL PRECISION TRANSCATHETER VALVE REPAIR SYSTEM RECEIVES FDA APPROVAL FOR DEGENERATIVE MITRAL REGURGITATION

IRVINE, Calif., Sept. 15, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), today announced the company's PASCAL Precision transcatheter valve repair system for transcatheter ...
Hosted on MSN

Edwards Lifesciences’ PASCAL System: A Promising Trial in Heart Valve Repair

Edwards Lifesciences Corp. ((EW)) announced an update on their ongoing clinical study. Edwards Lifesciences Corp. is currently conducting a pivotal clinical trial titled ‘Edwards PASCAL Transcatheter ...
Medscape

PASCAL Mitral Valve Repair Shines at 2 Years in CLASP

Transcatheter mitral valve repair with the PASCAL device showed high rates of survival and freedom from heart failure rehospitalization at 2 years in the single-arm, safety and efficacy CLASP study.